Treatment of refractory t-cell chronic lymphocytic leukemia with purine nucleoside analogues

Thomas E. Witzig, John J. Weitz, Joel H. Lundberg, Ayalew Tefferi

Research output: Contribution to journalArticle

20 Scopus citations


This report describes two cases of T-cell chronic lymphocytic leukemia (T-CLL) treated with purine nucleoside analogues. One patient had CD8+ CD3+ large granular lymphocytosis (LGL) producing transfusion-dependent anemia and was refractory to chemotherapy. Treatment with four cycles of fludarabine produced a clinical complete remission and a molecular genetic partial remission that has been durable for >15 months. The other patient had CD4+ T-prolymphocytic leukemia and was unresponsive to both fludarabine and 2-chlorodeoxy-adenosine. Further trials of these agents are warranted in T-CLL, especially the LGL variant.

Original languageEnglish (US)
Pages (from-to)137-139
Number of pages3
JournalLeukemia and Lymphoma
Issue number1-2
StatePublished - Jan 1 1994



  • Fludarabine
  • T-chronic lymphocytic leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this